Clinical trials: sponsored by Incyte Corporation
Polycythemia Vera
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically…
- Trial name
- NCT01632904
- Testing
- Ruxolitinib, Hydroxyurea (HU)
- Where
- 70 sites in United States, Belgium and 5 more
- Volunteers
- 110 people
- Sponsor
- Incyte Corporation
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Rheumatoid Arthritis
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
The purpose of this study is to understand the safety and tolerability of INCB018424 in patients with rheumatoid arthritis
- Trial name
- NCT00550043
- Testing
- INCB018424
- Where
- 15 sites in United States, Poland
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation
Rheumatoid Arthritis
INCB047986 in Rheumatoid Arthritis
The purpose of this study is to explore the safety, tolerability and efficacy of INCB047986, in subjects with moderate to severe rheumatoid arthritis.
- Trial name
- NCT02151474
- Testing
- INCB047986
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- Incyte Corporation
Myelofibrosis
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and…
- Trial name
- NCT01340651
- Testing
- Ruxolitinib
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Incyte Corporation
Type 2 Diabetes
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.
- Trial name
- NCT00698789
- Testing
- INCB019602, Metformin
- Where
- 22 sites in United States
- Volunteers
- 48 people
- Sponsor
- Incyte Corporation
Breast Cancer
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.
- Trial name
- NCT01254136
- Testing
- INCB007839 300mg BID, Trastuzumab, Vinorelbine
- Where
- 14 sites in United States
- Volunteers
- 20 people
- Sponsor
- Incyte Corporation
Insulin Resistance, Obesity
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.
- Trial name
- NCT00398619
- Testing
- INCB13739
- Where
- 2 sites in United States
- Sponsor
- Incyte Corporation